Efficacy and safety of oral semaglutide by baseline age in J apanese patients with type 2 diabetes: A subgroup analysis of the PIONEER 9 and 10 J apan trials-Reference-Cited by-同舟云学术

Efficacy and safety of oral semaglutide by baseline age in J apanese patients with type 2 diabetes: A subgroup analysis of the PIONEER 9 and 10 J apan trials

Published:2021-11-09 Issue:2 Volume:24 Page:321-326
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obesity Metabolism

Author:

Yamada Yuichiro¹^ORCID,Yabe Daisuke²³⁴^ORCID,Hertz Christin Løth⁵,Horio Hiroshi⁶,Nakamura Jiro⁷,Nielsen Anne Møller⁵^ORCID,Seino Yutaka¹⁸

Affiliation:

1. Center for Diabetes, Endocrinology and Metabolism Kansai Electric Power Hospital Osaka Japan

2. Department of Diabetes and Endocrinology Gifu University Graduate School of Medicine Gifu Japan

3. Yutaka Seino Distinguished Center for Diabetes Research Kansai Electric Power Research Institute Kobe Japan

4. Division of Molecular and Metabolic Medicine Kobe University Graduate School of Medicine Kobe Japan

5. Novo Nordisk A/S Søborg Denmark

6. Novo Nordisk Pharma Ltd Tokyo Japan

7. Division of Diabetes, Department of Internal Medicine Aichi Medical University School of Medicine Nagakute Aichi Japan

8. Kansai Electric Power Research Institute Kobe Japan

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/dom.14571

Reference14 articles.

1. Efficacy, safety and cardiovascular outcomes of once‐daily oral semaglutide in patients with type 2 diabetes: The PIONEER programme

2. β Cell Dysfunction Versus Insulin Resistance in the Pathogenesis of Type 2 Diabetes in East Asians

3. Incretin‐based drugs for type 2 diabetes: Focus on East Asian perspectives

4. Dose-response, efficacy, and safety of oral semaglutide monotherapy in Japanese patients with type 2 diabetes (PIONEER 9): a 52-week, phase 2/3a, randomised, controlled trial

5. Safety and efficacy of oral semaglutide versus dulaglutide in Japanese patients with type 2 diabetes (PIONEER 10): an open-label, randomised, active-controlled, phase 3a trial

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effects of switching from dipeptidyl peptidase 4 inhibitors to oral semaglutide on oxidative stress and glycemic variability in patients with type 2 diabetes: an open-label, prospective, randomized, multicenter, parallel-group comparison study;2024-09-09

2. PIONEER REAL Japan: Primary results from a multicenter, prospective, real‐world study of oral semaglutide in adults with type 2 diabetes in Japanese clinical practice;Journal of Diabetes Investigation;2024-08-22

3. Efficacy and safety of oral semaglutide in older patients with type 2 diabetes: a retrospective observational study (the OTARU-SEMA study);BMC Endocrine Disorders;2024-07-24

4. Efficacy and safety of switching from a dipeptidyl peptidase-4 inhibitor to oral semaglutide in Japanese patients with type 2 diabetes mellitus;Diabetology International;2024-05-30

5. Efficacy and safety of oral semaglutide in older patients with type 2 diabetes: a retrospective observational study (the OTARU-SEMA study);2024-02-07